Medtronic (NYSE:MDT) said last week that its board of directors approved the addition of $6 billion to its existing stock buyback program.
The existing $5 billion plan the board authorized in 2017 only has about $1.3 billion left, the Fridley, Minn.-based company said.
Publicly trading companies often initiate share repurchasing programs to drive up their stocks’ value.